Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Blood test sits at the center of this dementia and brain health question.
A new generation of blood tests can identify five biological markers associated with dementia risk—some of them detectable up to 25 years before symptoms appear. These biomarkers (p-tau181, p-tau217, neurofilament light chain, GFAP, and total tau or amyloid-β ratios) represent the most significant advance in early dementia detection in recent years, based on research published in Nature Medicine and Nature Communications in 2025.
The discovery has transformed our understanding of how the brain changes long before memory problems become noticeable—but the technology isn’t yet ready for widespread clinical screening of healthy people. This article explains what these five biomarkers are, what the research actually shows about their predictive power, why scientists consider them revolutionary, and what limitations exist before they become standard medical practice. We’ll also cover what you should know if you have a family history of dementia or if you’re considering early screening options.
Table of Contents
- Which Five Biomarkers Does the Blood Test Measure?
- How Accurate Is the Prediction? Understanding the Research Numbers
- Why These Specific Markers Reveal Brain Changes Years in Advance
- What Can You Actually Do With Blood Test Results Today?
- Important Limitations and Why This Isn’t Yet Clinical Practice
- What Happens When Biomarkers Progress—Tracking Disease Earlier
- The Future of Blood Biomarkers in Dementia Prevention and Care
- Conclusion
Which Five Biomarkers Does the Blood Test Measure?
The research identifies five key markers in blood that reflect what’s happening in the brain. Four of them—phosphorylated tau at position 181 (p-tau181), phosphorylated tau at position 217 (p-tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP)—showed the strongest associations with dementia development. A fifth category includes total tau and the amyloid-β 42/40 ratio, though these demonstrated weaker predictive power in the studies. Understanding what each marker means helps explain why they matter. Tau proteins are involved in supporting brain cell structure, but when they become phosphorylated (tagged with phosphate groups), they can accumulate and damage neurons.
NfL is released when nerve fibers break down, serving as a marker of neuronal injury. GFAP comes from glial cells—the brain’s support cells—and elevates when they become inflamed or stressed. Together, these markers paint a picture of brain deterioration happening silently, sometimes for decades before symptoms emerge. What makes this discovery remarkable is that these aren’t new proteins being discovered—they’re existing brain components we’ve long known about. What’s new is our ability to measure them accurately in blood samples instead of requiring expensive brain imaging or cerebrospinal fluid taps. For example, detecting p-tau217 in a simple blood draw is far more practical than a PET scan, which costs thousands of dollars and requires specialized equipment.
How Accurate Is the Prediction? Understanding the Research Numbers
The research shows impressive accuracy: the blood test achieved an area under the curve (AUC) ranging from 70.9% to 82.6% for predicting 10-year all-cause dementia and Alzheimer’s disease dementia risk. To put that in perspective, an AUC of 50% means the test performs no better than a coin flip, while 90% represents very strong predictive ability. These numbers place the blood test in the “good to excellent” range for medical prediction tools. However—and this is crucial—accuracy doesn’t mean certainty for individuals. Someone with elevated biomarkers might never develop dementia.
The UCSD study that tracked women found the test could predict dementia risk up to 25 years before symptoms, but individual outcomes vary widely. A woman with elevated p-tau181 at age 50 might develop cognitive impairment at 70, at 80, or possibly never in her lifetime. The test identifies statistical risk, not destiny. This distinction explains why blood-based biomarkers are not currently recommended for screening asymptomatic individuals in clinical practice. While the research is compelling, doctors don’t yet have proven interventions to recommend to someone who tests positive but shows no symptoms. Knowing your risk without actionable next steps can create unnecessary anxiety.
Why These Specific Markers Reveal Brain Changes Years in Advance
The brain‘s aging process involves cascading events. Amyloid-beta and tau proteins begin accumulating years before neurons die. As neurons weaken and die, they release NfL into the bloodstream. GFAP increases when glial cells—the brain’s immune and support system—become activated by inflammation and stress. Blood tests measure these events as they unfold, creating an early warning system. Among the five markers, p-tau217 and NfL showed the strongest associations with faster progression from mild cognitive impairment to dementia in the research.
This means if someone already has mild memory problems, these two markers were better predictors of how quickly symptoms would worsen. This distinction matters for doctors deciding how aggressively to monitor or treat someone who already shows cognitive decline. The reason these markers are so valuable is that the brain often changes silently. Someone can lose significant neurons and accumulate damaging proteins without noticing anything wrong. Traditional cognitive tests—remembering names, recalling stories—don’t detect these microscopic changes. A blood test provides an objective window into the brain’s hidden deterioration, something imaging or memory tests alone cannot do.
What Can You Actually Do With Blood Test Results Today?
If you could get a blood test tomorrow showing elevated p-tau181 and GFAP, what would change in your life right now? Unfortunately, very little from a treatment standpoint. This is the central limitation of the research’s current state: the biomarkers predict risk, but proven interventions for asymptomatic people with elevated markers don’t yet exist. That said, these results do provide value for people with other risk factors. If you already have mild cognitive impairment or early memory complaints, elevated biomarkers can accelerate your diagnosis and enroll you in disease-modifying trials. Several ongoing studies are testing newer drugs on people with biomarker evidence of Alzheimer’s pathology before symptoms appear.
Being identified as at-risk makes you eligible for these investigations, which might offer benefits or at minimum contribute to science. The practical approach today involves standard dementia prevention practices: managing blood pressure, maintaining cognitive activity, getting adequate sleep, exercising regularly, and controlling diabetes. These lifestyle factors help regardless of your biomarker status. Someone with elevated blood biomarkers who walks 30 minutes daily and learns new skills may benefit more than someone with normal biomarkers who is sedentary. The test provides risk information, but behavior still matters more.
Important Limitations and Why This Isn’t Yet Clinical Practice
Blood biomarkers have significant current limitations that explain why they aren’t standard screening yet. First, the studies showing 25-year prediction windows involved women specifically; the accuracy for men is less well established. Second, elevated biomarkers correlate with dementia risk, but correlation isn’t causation—having these proteins in your blood doesn’t automatically guarantee future cognitive decline. Third, these tests aren’t available through your regular doctor yet. They’re research tools at specialized centers, not routine lab work.
A UCSD study or a clinical trial might offer testing, but walking into your primary care doctor’s office asking for a p-tau217 blood test wouldn’t work—your insurance won’t cover it, and most doctors can’t order it. That infrastructure will take years to develop. Fourth, we still don’t know the optimal action to take once someone tests positive. Should you take a medication despite no symptoms? Should you double down on exercise and brain training? Should you plan life decisions around higher dementia risk? These questions await clinical trials and real-world evidence. Offering tests without clear next steps could harm more than help, creating anxiety and potentially driving unnecessary medication use.
What Happens When Biomarkers Progress—Tracking Disease Earlier
The research published in Nature Communications examined how these biomarkers progress as people move from normal cognition to mild cognitive impairment to dementia. What they found was that NfL and p-tau217 showed particularly strong associations with this progression, meaning these two markers change earliest and most noticeably as the brain’s condition worsens. This suggests future clinical use might involve serial testing—checking these biomarkers periodically over years to watch for acceleration.
If someone’s p-tau217 remains stable over five years, that’s reassuring; if it spikes upward, it might warrant closer monitoring or intervention. This sequential approach mirrors how doctors track cholesterol or blood pressure, building a trend rather than relying on a single number. The transition from one-time screening to trajectory monitoring represents how the field will likely evolve.
The Future of Blood Biomarkers in Dementia Prevention and Care
We’re at an inflection point. The science demonstrating these biomarkers’ predictive value is solid; the infrastructure to use them clinically is still being built. Within the next 3-5 years, we’ll likely see blood biomarker testing become available at major medical centers as an advanced diagnostic tool for people with cognitive complaints.
Within 10 years, as disease-modifying treatments improve, asymptomatic screening might become standard—similar to how colonoscopy is standard for cancer prevention despite not everyone who gets one developing cancer. The real promise lies in combining biomarkers with other information: genetics, lifestyle data, brain imaging when needed, and cognitive testing. No single blood test will become the complete answer to dementia risk. Instead, these biomarkers will become one piece of a more complete assessment, helping doctors and patients make earlier, more informed decisions about monitoring and prevention.
Conclusion
The discovery that five blood-based biomarkers can predict dementia risk up to 25 years in advance represents genuine scientific progress. P-tau181, p-tau217, neurofilament light chain, GFAP, and tau/amyloid measures show strong associations with future cognitive decline, with predictive accuracy in the 70-82% range. This technology offers real hope for earlier detection and eventually earlier intervention. For now, the practical reality is that these tests remain research tools, not clinical standards for healthy people.
If you have cognitive concerns or a strong family history of dementia, discussing blood biomarker testing with a neurologist or cognitive specialist is reasonable—they may recommend testing as part of a comprehensive evaluation. For asymptomatic individuals, the best dementia prevention approach remains unchanged: manage cardiovascular health, stay cognitively and physically active, prioritize sleep, and maintain social engagement. As the field evolves and treatments improve, blood biomarkers will become increasingly important. Until then, they represent a window into the future, not yet a clear path forward.
You Might Also Like
- Why Annual Flu Vaccination Is Now Linked to 12% Lower Dementia Risk in Adults Over 65
- Why Belly Fat in Midlife Is a Stronger Predictor of Dementia Risk Than Overall Body Weight
- The Personalized Dementia Risk Report Based on Your Medical History Available From Your Doctor
For more, see National Institute on Aging.
